PMID- 34937706
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20221115
IS  - 1600-0617 (Electronic)
IS  - 0905-9180 (Print)
IS  - 0905-9180 (Linking)
VI  - 30
IP  - 162
DP  - 2021 Dec 31
TI  - Interstitial pneumonia with autoimmune features: challenges and controversies.
LID - 10.1183/16000617.0177-2021 [doi]
LID - 210177
AB  - The presence of clinical, serological and/or radiological features suggestive, 
      but not confirmatory, of a defined connective tissue disease in patients with 
      interstitial lung disease is a relatively frequent occurrence. In 2015, the 
      European Respiratory Society and the American Thoracic Society proposed 
      classification criteria for the interstitial pneumonia with autoimmune features 
      (IPAF) research entity to capture such patients in a standardised manner, with 
      the intention of nurturing clinical research. This initiative resulted in the 
      publication of several series of IPAF patients, with significant variation 
      between cohorts in clinical characteristics, outcome and the application of IPAF 
      criteria in patient selection. From this increasing body of published work, it 
      has become apparent that revision of IPAF criteria is now required in order to 
      justify the eventual designation of IPAF as a standalone diagnostic term, as 
      opposed to a provisional entity put forward as a basis for clinical research. 
      This review covers the current state of IPAF, conclusions that can and cannot be 
      drawn from the IPAF evidence base, and ongoing uncertainties that require further 
      expert group consideration.
CI  - Copyright (c)The authors 2021.
FAU - Mackintosh, John A
AU  - Mackintosh JA
AUID- ORCID: 0000-0002-5254-4144
AD  - Dept of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia 
      john.mackintosh@health.qld.gov.au.
FAU - Wells, Athol U
AU  - Wells AU
AD  - Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial 
      College, London, UK.
FAU - Cottin, Vincent
AU  - Cottin V
AUID- ORCID: 0000-0002-5591-0955
AD  - National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, 
      Hospices Civils de Lyon, Lyon, France.
AD  - Claude Bernard University Lyon 1, University of Lyon, INRAE, IVPC, UMR754, member 
      of ERN-LUNG, Lyon, France.
FAU - Nicholson, Andrew G
AU  - Nicholson AG
AD  - Dept of Histopathology, Royal Brompton Hospital, London, UK.
AD  - National Heart and Lung Institute, Imperial College, London, UK.
FAU - Renzoni, Elisabetta A
AU  - Renzoni EA
AD  - Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
AD  - Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial 
      College, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211222
PL  - England
TA  - Eur Respir Rev
JT  - European respiratory review : an official journal of the European Respiratory 
      Society
JID - 9111391
SB  - IM
CIN - Eur Respir Rev. 2021 Dec 22;30(162):. PMID: 34937707
MH  - *Autoimmune Diseases/diagnosis
MH  - Humans
MH  - *Lung Diseases, Interstitial/diagnostic imaging/therapy
PMC - PMC9488577
COIS- Conflict of interest: J.A. Mackintosh has nothing to disclose. Conflict of 
      interest: A.U. Wells reports personal fees from Roche, Boehringer Ingelheim and 
      Bayer outside the submitted work. Conflict of interest: V. Cottin reports 
      personal fees and non-financial support from Actelion; grants, personal fees and 
      non-financial support from Boehringer Ingelheim; personal fees from Bayer/MSD; 
      personal fees and non-financial support from Roche/Promedior; and personal fees 
      from Sanofi, Celgene/BMS, Galapagos, Galecto, Shionogi, AstraZeneca, Fibrogen, 
      RedX and PureTech, outside the submitted work. Conflict of interest: A.G. 
      Nicholson reports consulting fees received from Galapagos, Boehringer Ingelheim, 
      Roche and Medical Quantitative Image Analysis in relation to idiopathic pulmonary 
      fibrosis, outside the submitted work; and payment for educational activities in 
      relation to ILD outside the submitted work. Conflict of interest: E.A. Renzoni 
      reports receiving grants or contracts from Boehringer Ingelheim outside the 
      submitted work; lecture fees paid to the institution from Boehringer Ingelheim, 
      Roche and Chiesi outside the submitted work; and support for attending ATS 
      conference from Boehringer Ingelheim outside the submitted work.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/25 06:00
PMCR- 2021/12/22
CRDT- 2021/12/23 05:33
PHST- 2021/07/24 00:00 [received]
PHST- 2021/09/01 00:00 [accepted]
PHST- 2021/12/23 05:33 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2021/12/22 00:00 [pmc-release]
AID - 30/162/210177 [pii]
AID - ERR-0177-2021 [pii]
AID - 10.1183/16000617.0177-2021 [doi]
PST - epublish
SO  - Eur Respir Rev. 2021 Dec 22;30(162):210177. doi: 10.1183/16000617.0177-2021. 
      Print 2021 Dec 31.